Johnson & Johnson said on Thursday its cancer drug combination helped patients with a type of non small-cell lung cancer live longer without the disease worsening compared with AstraZeneca's blockbuster cancer drug Tagrisso.
J&J's therapy combination of antibody treatment Rybrevant and experimental drug lazertinib showed a clinically meaningful improvement in progression-free survival rate in patients.
The drugmaker expects the combination to become a first-line treatment for non small-cell lung cancer (NSCLC) patients with a type of mutation in EGFR protein that causes rapid tumor cell growth.
A rival treatment combining AstraZeneca's Tagrisso and chemotherapy also recently succeeded in a late-stage study.
The trial showed that the Tagrisso-chemo combination reduced the risk of disease progression or death by 38% when compared to Tagrisso alone.
The bar for J&J's study was high because Tagrisso has a compelling first line commercial profile, and physicians may prefer use of a single therapy compared to combinations for first line treatment, said Leerink Partners analyst David Risinger.
https://finance.yahoo.com/news/1-j-js-lung-cancer-114732347.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.